Rebuilding Trust and Reshaping Global Health Finance: H20 Summit Lays Groundwork for G20 Health Agenda From June 19 to 20, global leaders in health and development converged in Geneva for the annual Health20 (H20) Summit. The high-level event, organized by…
Merck Awards 2025 North American Advance Biotech Grant to Neoclease for AI-Driven Parkinson’s Gene Editing Therapy Merck, a global leader in science and technology, has officially named Neoclease as the recipient of its 2025 North American Advance Biotech Grant, recognizing…
FDA Approves ANDEMBRY (garadacimab-gxii) The First Once-Monthly Prophylactic HAE Therapy Targeting Factor XIIa CSL a leading biotechnology company with a strong track record of developing innovative medicines for patients with rare and serious disorders, today announced that the U.S. Food…
Dapirolizumab Pegol Shows Disease Activity Reduction and Fatigue Improvement in SLE at EULAR 2025 UCB and Biogen today presented additional and detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel, Fc-free, anti-CD40 Ligand (anti-CD40L)…
Merck Highlights Positive Enpatoran Phase 2 WILLOW Study Data in SLE at EULAR 2025 Merck, a leading science and technology company, today presented new and detailed results from its Phase 2 WILLOW study, emphasizing the potential of its investigational oral…
EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and sustained reduction in disease flares and key disease activity markers…
Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive new findings from their Phase 3 PHOENYCS GO clinical trial…
WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health Organization (WHO) convened the fourth meeting of the International Health…
WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN Pharmaceuticals (HKEX: 2561), a clinical-stage biopharmaceutical company dedicated to advancing…
Sanofi Ramps Up Early Global Distribution of Beyfortus to Meet Growing RSV Season Demand, Enhancing Protection for Infants Worldwide In a proactive move to ensure readiness for the 2025-2026 respiratory syncytial virus (RSV) season, Sanofi has announced that shipments of…
WHO Advances Global Chemical Hazard Preparedness with New Comprehensive Online Training Series In a recent address to the Seventy-eighth World Health Assembly, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), brought critical attention to an often-overlooked public…
Bayer’s Nubeqa Secures Third FDA Approval, Expanding Prostate Cancer Treatment Landscape Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted approval for a third indication of its oral androgen receptor inhibitor, Nubeqa™ (darolutamide). This latest approval…